HopeStage
Back to all studies
TerminatedNCT03230864

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

This study evaluates the effectiveness of Lu AF35700 for people with schizophrenia.

Medication studyAges 18+Multiple countries
The study in practice

Understand this study

What is this study about?

This study evaluates the effectiveness of Lu AF35700 for people with schizophrenia.

Who could participate?

Listed age limits: from 18 years.

Listed locations
San Diego and 40 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 20, 2017
Recruitment status
Terminated
Enrollment listed in the registry
119
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, United Kingdom, Bulgaria, ...
Age range
Over 18 Years
Official registry ID
NCT03230864
Official title
Show the full official title

Interventional, Randomized, Double-blind, Active-controlled Study of the Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

Recruitment & locations

Terminated

San Diego, United States · Atlanta, United States · Chicago, United States

33 more locations
  • Fall River, United States
  • Worcester, United States
  • Ann Arbor, United States
  • Kalamazoo, United States
  • St Louis, United States
  • Omaha, United States
  • Salt Lake City, United States
  • Kardzhali, Bulgaria
  • Novi Iskar, Bulgaria
  • Pleven, Bulgaria
  • Radnevo, Bulgaria
  • Sofia, Bulgaria
  • Targovishte, Bulgaria
  • Aizu-Wakamatsu, Japan
  • Fukushima, Japan
  • Ichikawa, Japan
  • Kashihara, Japan
  • Kita-ku, Japan
  • Kitakyushu, Japan
  • Kodaira, Japan
  • Kumamoto, Japan
  • Kunigami, Japan
  • Toyoake, Japan
  • Lipetsk, Russia
  • Saint Petersburg, Russia
  • Samara, Russia
  • Tomsk, Russia
  • Yaroslavl, Russia
  • Yekaterinburg, Russia
  • Edinburgh, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the effectiveness of Lu AF35700 for people with schizophrenia.

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Does this study involve medication?

Yes. The study involves medication, including Lu AF35700, Risperidone and Olanzapine.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies